Heart failure & cardiomyopathies
Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT
Primary result · Change in eGFR from baselineResult — go to the resultLeast squares mean difference 3.99 mL/min/1.73 m² 95% CI 1.31–6.68Authors' conclusion
Renal function deteriorates over time in patients with ATTR-CM, and tafamidis treatment was associated with a reduction in this deterioration, and a higher incidence of improved eGFR and CKD staging over 30 months compared with placebo.
Study context
- Population
- Patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
- Participants
- 264 vs 177
- Comparison
- Tafamidis vs placebo
- Tafamidisn = 264
- Placebon = 177reference
- Primary endpoint
- Change from baseline in eGFR
- Follow-up
- 30 months
Primary result
Change in eGFR from baseline
Least squares mean difference
3.99 mL/min/1.73 m²
95% CI 1.31–6.68
P = 0.004
Tafamidisvs Placebo
least squares mean difference 3.99 mL/min/1.73 m² (95% CI 1.31–6.68); P = 0.004
As reported in the abstract
Further findings
Baseline eGFR · mean baseline
| Outcome | Tafamidis | Placebo | Estimate | P value | |
|---|---|---|---|---|---|
| Improvement in CKD staging (completers)Patients who completed ATTR-ACT | 17.7% | 7.2% | OR 2.75 (95% CI 1.10–6.90) | P = 0.034 | |
| Composite renal endpoint (all-cause death, dialysis, kidney transplant or ≥30% eGFR decline), time to first eventCrude rates | HR 0.73 (95% CI 0.54–0.99) | P = 0.040 | |||
| Crude rate | 34.5% | 44.1% | |||
| 0.10.31310Ratio (log scale) |
Original publication
Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT. JACC CardioOncol. Published 16 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →